The DOI matches its Crossref record.
Daclizumab versus Antithymocyte Globulin in High-Immunological-Risk Renal Transplant Recipients
Open accessAbstract
Nondepleting anti-CD25 monoclonal antibodies (daclizumab) and depleting polyclonal antithymocyte globulin (Thymoglobulin) both prevent acute rejection, but these therapies have not been directly compared in a high-risk, HLA-sensitized renal transplant population. We randomly assigned 227 patients, who were about to receive a kidney graft from a deceased donor, to either Thymoglobulin or daclizumab if they met one of the following risk factors: current panel reactive antibodies (PRA) >30%; peak PRA >50%; loss of a first kidney graft from rejection within 2 yr of transplantation; or two or three previous grafts. Maintenance immunosuppression comprised tacrolimus, mycophenolate mofetil, and steroids. Compared with the daclizumab group, patients treated with Thymoglobulin had a lower incidence of both biopsy-proven acute rejection (15.0% versus 27.2%; P = 0.016) and steroid-resistant rejection (2.7% versus 14.9%; P = 0.002) at one year. One-year graft and patient survival rates were similar between the two groups. In a comparison of rejectors and nonrejectors, overall graft survival was significantly higher in the rejection-free group (87.2% versus 75.0%; P = 0.037). In conclusion, among high-immunological-risk renal transplant recipients, Thymoglobulin is superior to daclizumab for the prevention of biopsy-proven acute rejection, but there is no significant benefit to one-year graft or patient survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Delayed Graft Function in the Kidney Transplant
Siedlecki, A., Irish, W., & Brennan, D. C. (2011) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2011.03754.x · Cited by 817
Alemtuzumab Induction in Renal Transplantation
Hanaway, M. J., Woodle, E. S., Mulgaonkar, S., Peddi, V. R., Kaufman, D. B., First, M. R., Croy, R., & Holman, J. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009546 · Cited by 383
Interleukin 2 receptor antagonists for kidney transplant recipients
Webster, A. C., Ruster, L. P., McGee, R. G., Matheson, S. L., Higgins, G. Y., Willis, N. S., Chapman, J. R., & Craig, J. C. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003897.pub3 · Cited by 268
Impact of CYP3A5 genotype on de-novo LCP tacrolimus dosing and monitoring in kidney transplantation
Rao, N., Carcella, T., Patel, N., Bartlett, F., Posadas, M. A., Casey, M., Dubay, D. A., & Taber, D. J. (2023) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000494 · Cited by 5
Metadata
- Authors
- Noe[Combining Diaeresis]l, C., Abramowicz, D., Durand, D., Mourad, G., Lang, P., Kessler, M. G. A., Charpentier, B., Touchard, G., Berthoux, F. C., Merville, P., Ouali, N., Squifflet, J.-P., Bayle, F. C., Wissing, K. M., & Hazzan, M.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2009-06
- Volume
- 20
- Issue
- 6
- Pages
- 1385-1392
- ISSN
- 1046-6673 (ISSN-L)
- OpenAlex
- W2135136335
- Cited by
- 199
- References
- 0
- FWCI
- 7.87
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Daclizumab versus Antithymocyte Globulin in High-Immunological-Risk Renal Transplant Recipients. https://app.cochat.ai/papers/10.1681/asn.2008101037
- The paper
- Noe[Combining Diaeresis]l, C., Abramowicz, D., Durand, D., Mourad, G., Lang, P., Kessler, M. G. A., Charpentier, B., Touchard, G., Berthoux, F. C., Merville, P., Ouali, N., Squifflet, J.-P., Bayle, F. C., Wissing, K. M., & Hazzan, M. (2009). Daclizumab versus Antithymocyte Globulin in High-Immunological-Risk Renal Transplant Recipients. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.2008101037
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.